Everything below concerns obesity research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
The Russell 3000 is primarily subdivided into two other indices, the large-cap Russell 1000 and the small-cap Russell 2000. Those two indices are disjoint, and combining them results in exactly the Russell 3000. As of April 30, 2025, the Russell 1000 comprised about 95% of the Russell 3000's total market capitalization, and the Russell 2000 comprised the approximate remaining 5%. Most other indices in the Russell US series are also subsets of the Russell 3000.
== Evolution == GPxs are a key part of animal (including human) antioxidant defenses. They are also find in bacteria, plants, and fungi. GPx was the first selenoprotein discovered, with a highly reactive Sec residue at the active site. Comparison of GPx sequences from all these types of life suggest that the ancestral GPx did not contain selenium; instead, acquision of Sec happened early in animal evolution, before the sponges diverged from other animals. Humans have eight Gpx genes, but only five of them contain Sec (GPX1, GPX2, GPX3, GPX4, GPX6). The non-existence of Sec in GPX7 and GPX8 appears to be universal among animals. The loss of Sec (by replacement with Cys) in GPX5 was, however, a relatively recent event that happened after the divergence of humans from rodents. Rodents have independently lost the Sec in Gpx6, but kept it in their version of Gpx5. Human GPX5 and rodent Gpx6 retain vestigial SECIS elements indicative of their past.
== Structure == ACTH receptors are the shortest of the melanocortin receptor family and are the smallest known G-coupled receptors. Both human and bovine ACTH receptors are synthesized as 297 residue long proteins with 81% sequence homology. There are currently no available protein X-ray crystallography structures for the ACTH receptor available in the Protein Data Bank; while the ACTH receptor and the β2 adrenergic receptor are relatively distantly-related with a sequence identity of approximately 26%, MC2R investigators such as David Fridmanis have assumed that the folded surfaces of both receptors that are responsible for binding Gαs should be very similar and use conserved motifs. The full length sequence of MC2R includes seven hydrophobic domains that are predicted as transmembrane segments. In the third intracellular loop of the receptor a protein kinase A and protein kinase c phosphorylation motifs have been detected. ACTH receptors also require the binding of melanocortin-2 receptor accessory protein-1 (MRAP1) without which ACTH receptors cannot bind ACTH. Without MRAP, the receptor is degraded in the endoplasmic reticulum, but with MRAP, the receptor is glycosylated and expressed on the cell plasma membrane.
Agragen, in collaboration with University of Alberta – docosahexaenoic acid and human serum albumin in flax Chlorogen, Inc. – cholera, anthrax, and plague vaccines, albumin, interferon for liver diseases including hepatitis C, elastin, 4HB, and insulin-like growth factor in tobacco chloroplasts. Went out of business in 2007. Dow Chemical Company made a deal with Sunol Molecular in 2003 to develop antibodies against tissue factor in plants and in mammalian cell culture and to compare them. In 2005 Sunol sold all its tissue factor antagonists to Tanox, which in turn was bought by Genentech in 2003. Genentech licensed the tissue factor program to Altor in 2008 Altor is itself a spinout from Sunol. The product under development, ALT-836, formerly known as TNX-832 and Sunol-cH36, is not the plant-produced antibody, but rather is a mammalian antibody, more specifically, a chimeric antibody produced in a hybridoma. Epicyte – spermicidal antibodies in corn Epicyte was purchased by Biolex in 2004 at which time Epicyte's portfolio was described as "focused on the discovery and development of human monoclonal antibody products as treatments for a wide range of infectious and inflammatory diseases." Large Scale Biology Corporation (LSBC) (bankrupt) – used Tobacco mosaic virus to develop reagents and patient-specific vaccines for Non-Hodgkin's lymphoma, Papillomavirus vaccine, parvovirus vaccine, alpha galactosidase for Fabry disease, lysosomal acid lipase, aprotinin, interferon Alpha 2a and 2b, G-CSF, and Hepatitis B vaccine antigens in tobacco.
In 1949, after the war and Allied occupation, Germany was organised into two separate polities with limited sovereignty: the Federal Republic of Germany (FRG), or West Germany, and the German Democratic Republic (GDR), or East Germany. The FRG was a founding member of the European Economic Community, while the GDR was a communist Eastern Bloc state and a founding member of the Warsaw Pact. After the fall of the communist-led government in East Germany, German reunification saw the former East German states join the FRG on 3 October 1990. Germany is a developed country with a strong economy, the largest in Europe by nominal GDP. As a major force in several industrial, scientific and technological sectors, Germany is both the world's third-largest exporter and third-largest importer. Widely considered a great power, Germany is part of multiple international organisations and forums. It has the third-highest number of UNESCO World Heritage Sites: 55, of which 52 are cultural.
Sources: en.wikipedia.org
Pregnancy-specific biological substances, which include the placenta, umbilical cord, amniotic fluid, and amniotic membrane are being studied for a number of health uses. For example, Placental-derived stem cells are being studied so they can serve as a potential treatment method for cell therapy. Hepatocyte-like cells (HLC) are generated from differentiated human amniotic epithelial cells (hAEC) that are abundant in the placenta. HLC may replace hepatocytes for hepatocyte transplantation to treat acute or chronic liver damage. Recent research has shown that the placenta and placenta derivatives are being regenerative cell therapies and also includes immunological features. Placenta structures consist of unique physiognomies. Placenta's structure not only regulates its function but also gives the probability of efficient use in clinics and in biotechnology. According to a research study by Bhattacharya N., Anemia caused by Diabetes mellitus in patients with albuminuria can be treated with cord blood transfusion. The research showed increased in albumin per gram of creatinine that assessed for albuminuria for patients that received cord blood transfusions.
== Commercialization == 1-MNA has been approved for use in food products in the form of 1-MNA chloride. The approval process in the European Union was successfully completed by PHARMENA SA. In 2017, the European Food Safety Authority (EFSA) confirmed the safety of 1-MNA chloride in food supplements, leading to its authorization in 2018 under EU Regulation 2018/1123. 1-MNA chloride is currently used in dietary supplements. Other chemical forms of 1-MNA are not currently allowed on the market as food.
After a twenty-year hiatus, the station was officially relaunched on 4 April 2011. Its radio counterpart Radio Mogadishu also broadcasts from the capital. Somaliland National TV and Puntland TV and Radio air from the northern regions. Additionally, Somalia has several private television and radio networks. Among these are Horn Cable Television and Universal TV. The political Xog Doon and Xog Ogaal and Horyaal Sports broadsheets publish out of the capital. There are also a number of online media outlets covering local news, including Garowe Online, Wardheernews, and Puntland Post. The internet country code top-level domain (ccTLD) for Somalia is .so. It was officially relaunched on 1 November 2010 by.SO Registry, which is regulated by the nation's Ministry of Posts and Telecommunications. In November 2013, following a Memorandum of Understanding signed with Emirates Post in April of the year, the federal Ministry of Posts and Telecommunications officially reconstituted the Somali Postal Service (Somali Post). In October 2014, the ministry also relaunched postal delivery from abroad.
== Taxonomy == The genus was given its name by Carl Linnaeus in 1753, in describing the European species E. alpinum. The name is a Latinized version of a Greek name for an unidentified plant, epimedion, that is mentioned in Pliny's Natural History (xxvii.57). The meaning of the original name is unclear.
Some unregulated transdermal progesterone products contain "wild yam extract" derived from Dioscorea villosa, but there is no evidence that the human body can convert its active ingredient (diosgenin, the plant steroid that is chemically converted to produce progesterone industrially) into progesterone.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.